/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts, is a global leader in biotechnology and precision medicine. With a market cap of $106.1 billion, Vertex pioneers innovation by developing transformative therapies targeting serious diseases, including cystic fibrosis and genetic disorders. The company is set to release its Q4 earnings on Wednesday, Feb. 3.
Ahead of the event, analysts expect Vertex to report a profit of $3.41 per share on a diluted basis, down 4.5% from $3.57 per share in the year-ago quarter. The company beat the consensus estimates in two of the last four quarters while missing on two other occasions.